OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

Immunocompromised people — such as those undergoing cancer treatment, organ transplant recipients, or people with HIV — are at high risk of severe COVID-19 and can carry the virus for a long time. This randomized trial tests different combinations of antiviral medications to find out which strategy works best for treating COVID-19 in this vulnerable population. You may be eligible if: - You are 16 or older (18+ in Italy and Norway) with a confirmed COVID-19 infection - You have a mild to moderate case (not requiring oxygen specifically for COVID) - You are immunocompromised (e.g., on immunosuppressants, chemotherapy, transplant recipient, HIV with low CD4, or certain blood cancers) - You are willing and able to comply with study requirements You may NOT be eligible if: - Your COVID PCR CT value is 30 or above (meaning very low viral load) - You weigh less than 40 kg - You have severe liver disease (Child-Pugh C) or high liver enzymes (AST/ALT > 5x normal) - You have taken certain antiviral treatments for COVID in the 14 days before enrollment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.